Patient Insight Partnership with Raremark.

Uncover insights into the entire patient journey and create truly patient-centric drug development and commercialisation programs

To produce medicines with more value and better outcomes, patient engagement and insight is vital. It’s the bedrock of the solutions and services we develop at Prime Global.

To supercharge our insight-driven and patient-centred services, we’ve come together with Raremark, a first of its kind patient experience network, to transform solutions and outcomes for patients with rare diseases.

Raremark is a community for patients with rare diseases and its patient-powered knowledge platform, Xperiome, provides a patient insight, from patient recorded outcomes (PROs) to real world evidence (RWE) and more, to deliver innovative new therapies faster and smarter for the pharmaceutical industry.

To access patients with rare diseases, we use Raremark’s Xperiome platform, which utilises novel design and behavioural science techniques to create unique patient journeys, whilst providing biopharmaceutical companies with access to engaged and consented populations to recruit to studies and generate anonymized and aggregated patient data unavailable elsewhere – supporting clinical development, accelerating speed to market and facilitating the evaluation of new treatments.

Raremark has engaged communities in many rare disease areas. Here are some of their most established, not limited to:  

  • Adrenoleukodystrophy 
  • Cystic Fibrosis 
  • Haemophilia 
  • Idiopathic pulmonary fibrosis (IPF) 
  • Myasthenia Gravis 
  • Pouchitis 
  • Sanfilippo Syndrome (MPS III) 
  • Sickle Cell  
  • Urea Cycle Disorder 
  • Urea Cycle Disorder sub-population – Ornithine transcarbamylase (OTC) deficiency 

“By combining Raremark’s cutting-edge Xperiome platform for patients with our 23 years of award-winning medical communications experience, we can deliver patient-centric services and solutions that improve outcomes for both pharma and, most importantly, patients.”

Graeme Peterson, Prime Global CEO

At the forefront of innovation in patient engagement.  

Focusing on the needs of patients is the key to powerful communications that make a tangible difference to patient outcomes. Our joint approach uncovers insights into the entire patient journey allowing the creation of truly patient-centric drug development and commercialisation programs.

We can bring together patients and researchers and insight informed services and solutions to improve lives. Our highly qualified scientific teams can work with Raremark to access your rare patient populations; get in touch to find out how we can help you accelerate the development and reach of new treatments today.

With health technology review bodies focusing on the ‘real world’ impact on patients, their input is no longer a nice to have, it’s a must.

Get in touch to find out how we can help you integrate the patient voice into your value demonstration and access agenda for rare diseases.

Susie MarriottPatient Insight Partnership with Raremark